Anti-GD2 antibody-containing immunotherapy post-consolidation therapy for people with high-risk neuroblastoma treated with autologous hematopoietic stem cell transplantation

To assess whether people with high-risk neuroblastoma have an additional benefit in terms of survival and tumor response of anti-GD2 antibody added to the post-consolidation therapy after high-dose chemotherapy and autologous hematopoietic stem cell transplantation as compared to placebo or no therapy, and whether anti-GD2 antibody has adverse events and impact on quality of life.

This is a protocol.

Share/Save